Literature DB >> 6628511

Erythromycin absorption in healthy volunteers from single and multiple doses of enteric-coated pellets and tablets.

T Hovi, K Josefsson, O V Renkonen.   

Abstract

The absorption of erythromycin from two different enteric-coated preparations was evaluated in three groups of healthy volunteers. After a single dose, taken after an overnight fast, absorption was significantly better from enteric-coated pellets than from tablets; both the mean peak serum concentration and the peak mean level were higher (p less than 0.01) in all three groups, and the mean area under the serum concentration-time curve (AUC) was at least 65% larger. Eight out of 23 subjects showed no or only a very low serum concentration after the enteric-coated tablets. In a follow-up study, 250 mg doses were given 6-hourly for 3 days, and again the mean maximum serum concentration was significantly higher (p less than 0.05) after the pellets. In conclusion, enteric-coated pellets led to more regular and predictable absorption of erythromycin than did coated tablets.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6628511     DOI: 10.1007/bf00543802

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Studies on absorption of a newly developed enteric-coated erythromycin base.

Authors:  P J McDonald; L E Mather; M J Story
Journal:  J Clin Pharmacol       Date:  1977-10       Impact factor: 3.126

2.  [Effect of dissolving pH of enteric coating agent on bioavailability of enteric coated tablets of erythromycin in man (author's transl)].

Authors:  Y Watanabe; M Sano; K Motohashi; R Yoneda
Journal:  Yakugaku Zasshi       Date:  1978-08       Impact factor: 0.302

3.  Pharmacokinetics of a new, microencapsulated erythromycin base after repeated oral doses.

Authors:  K Josefsson; M Steinbakk; T Bergan; T Midtvedt; L Magni
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

4.  Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base.

Authors:  K Josefsson; T Bergan; L Magni
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

5.  Influence of study design in assessing food effects on absorption of erythromycin base and erythromycin stearate.

Authors:  A R DiSanto; D J Chodos
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

6.  The influence of food on the bioavailability of new formulations of erythromycin stearate and base.

Authors:  J Rutland; N Berend; G E Marlin
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

  6 in total
  4 in total

Review 1.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

2.  Effect of concomitant food intake on absorption kinetics of erythromycin in healthy volunteers.

Authors:  T Hovi; M Heikinheimo
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin.

Authors:  A A Somogyi; F Bochner; D Hetzel; D B Williams
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

4.  Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils.

Authors:  R Anderson; A J Theron; C Feldman
Journal:  Inflammation       Date:  1996-12       Impact factor: 4.092

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.